SEC investigation targets Inamed
This article was originally published in The Gray Sheet
Executive Summary
Adequacy of disclosures concerning firm's silicone gel-filled breast implants is under Securities and Exchange Commission review, Inamed reports in 10-K filing March 16. "We believe that our disclosures regarding our silicone gel-filled breast implant products have been and are in compliance with federal securities laws," Inamed maintains, adding that those disclosures represent $3.4 mil., or less than 1% of its 2004 revenue. FDA's General & Plastic Surgery Devices Panel is slated to consider Inamed and Mentor's respective silicone gel breast implant premarket applications April 11-13 (1"The Gray Sheet" March 7, 2005, In Brief)...